Background: This study examines our institutional ventricular assist devices (VADs) experience over two decades to understand trends towards predictors of mortality. Methods: Retrospective study of patients aged 0-21 years supported with a VAD from January 1996 to May 2015. Patient data was examined pre and post-VAD implant among survivors and non-survivors. Results: Thirty-six patients identified (8 supported by Thoratec® VAD and 28 supported by EXCOR Berlin Heart®). Patient's diagnosis included dilated cardiomyopathy (DCM) (n = 19,53%), congenital heart disease (CHD) (n = 12,33%), and other (n = 5,14%). Median age and body surface area (BSA) were 1.0 years[0-7 years] and 0.41[0.24-0.92], respectively. Survival to discharge was 75% with no deaths with DCM. The survival rate for patients with CHD was 42%. Univariate analysis showed diagnosis of CHD, smaller BSA and respiratory failure post-implant (Intermacs criteria) as risk factors for mortality. Median duration of VAD support was lower in non-survivors, 14 vs 63 days (p = 0.03). Renal function at time of transplant or death was normal/ pRIFLE Risk category in 20(74%) of survivors and 2(22%) of non-survivors (p = 0.06). Post-implant, peak total bilirubin in the first week trended lower in survivors (p = 0.06). Conclusions: Persistent end-organ impairment in the first 2 weeks after VAD placement could be a useful prognostic marker for survival to transplant.
Introduction
Despite marked improvements in the management of pediatric patients with acquired and congenital heart disease, the number of patients needing a heart transplant continues to increase. Due to the limited availability of organs, this population is at high risk of mortality while waiting for a heart transplant [1] . Mechanical Circulatory Support (MCS) devices have been used to extend patient survival while awaiting heart transplant. The first MCS was developed in the 1960's for adult patients in heart failure, with the first FDA approval granted in 1994. In the early 2000's, adult ventricular assist devices (VAD), such as the Thoratec and HeartMate I®, were used in adolescents. Being initially developed for the adult population, their use was limited in the pediatric population to teenagers and children with a larger body surface area (BSA). Thus, clinicians were limited to the use of extracorporeal membrane oxygenation (ECMO) and centrifugal pumps as their only option to bridge smaller children to transplantation. Unfortunately, these devices are suitable only for short-term use and are associated with serious adverse events when used for longer periods [2] [3] [4] .
With technical and design improvements, VADs were developed for use in pediatric patients. Yet, the variety of VADs available for long-term support in the pediatric population continues to be limited, with only two devices having received FDA approval; the Berlin Heart EXCOR® VAD and the MicroMed HeartAssist 5 (DeBakey VAD®). The DeBakey VAD was the first FDA approved VAD as a bridge to transplant for the pediatric population, but limited to ages 5-16 years and with a BSA of 0.7-1.5 m 2 [2] . Followings its initial compassionate use, in 2012, the Berlin Heart EXCOR® VAD was approved by the FDA for use in children of all ages, including newborns, and is currently the most widespread pediatric VAD in the United States [3, 5] . Recent studies have shown that the Berlin Heart EXCOR, as well as newer devices including Heart Ware, Heart Mate II and SynCardia Total Artificial Heart (used under off label or compassionate use), present a suitable option for pediatric patients waiting for a heart transplant with observed survival rates of 60-90%. Yet, infections, bleeding and neurological events remain the most common morbidity factors during VAD support [6] [7] [8] . Prior studies have identified pre-and post-VAD implant factors associated with poor prognosis. Yet, some of these factors, as well as the incidence of adverse events, seem to vary by institution. These variations may be due to institution's experience, surgical approach, post-VAD management and patient selection bias, among others. Hence, we sought to describe our experience using VADs across two decades as a bridge to pediatric heart transplant in order to understand our institution's trends towards predictors of mortality post-implant.
Materials and methods
This study was a single-center retrospective chart review. The study was approved by the Institutional Review Board at the University of Florida. All patients under 21 years of age who underwent VAD implantation at our center between January 1st, 1996 and June 30, 2015 were included. Our primary outcome was survival to discharge post-transplant. Secondary outcomes included the incidence of major serious adverse events (SAE), including major bleeding, sepsis/infection and stroke/brain hemorrhage. SAE were described based on the Inter Agency Registry for Mechanically Assisted Circulatory Support (Intermacs) adverse events definition [9] .
Demographic data collected included race, ethnicity, blood type, age, weight, height, BSA, BMI and diagnosis. VAD related data included duration of support, duration of mechanical ventilation, implanted pump size, anticoagulation management, surgical information, type of VAD support (BiVAD vs LVAD), as well as number of VAD changes. Laboratory results, including electrolytes, hepatic panel including peak bilirubin prior to implant and peak bilirubin in the first week after implant, blood gas, coagulation factors, chemistry and complete blood count were collected pre-and post-implantation. Other relevant parameters were collected pre-and post-implantation including inotropic support, use of ECMO and duration of ECMO. Increase in liver enzymes was described as ALT and AST N 400 IU/L, Acute Kidney Injury (AKI) was determined using the pediatric RIFLE score (pRIFLE; glomerular filtration rate estimated using the Schwartz formula) [10] . Neurological outcome on chart review was classified based on the Pediatric Overall Performance Category Score (POPC score) [11, 12] .
Anticoagulation during VAD support
All patients were managed under the standardized Edmonton protocol for anticoagulation and antiplatelet therapy. Patients were initiated on unfractionated heparin infusion 24-48 h post implantation and transitioned to low-molecular-weight heparin or warfarin. Two patients had suspected Heparin Induced Thrombocytopenia (HIT) and received Bivalirudin instead of heparin. Antiplatelet treatment included the use of aspirin and dipyridamole. The titration of anticoagulation and antiplatelet therapy was based on combined data from thromboelastogram (TEG) results, platelet function studies and partial thromboplastin time (PTT).
Statistical analysis
All analyses were performed using the R statistical software package (Vienna, V. 3.1.3). Data was analyzed using Fisher's exact tests (categorical variables) and Mann-Whitney tests (continuous variables) to assess the association of each factor with survival on VAD. Due to our small sample size p value b 0.1 was considered a trend to clinical significance. Kaplan-Meier method was used to estimate survival time on VAD. Due to sample size, analysis was limited to univariate analysis.
Results
Patient demographics are summarized in Table 1 . There were 36 patients supported with a VAD (8 Thoratec® and 28 Berlin Hearts®) during our study period. Twenty-nine (80.5%) of the patients were supported with BiVADs and 7 (19.5%) had single VAD support. Our institution has a low threshold for the placement of BiVADs in the context of suspected right heart dysfunction. In the initial decade from 1996 to 2006, the only device used was the Thoratec VAD system. In 2006, the Berlin EXCOR was introduced at our institution and became the mainstay of therapy. One patient was implanted with the SynCardia 70 cc total artificial heart but was not included in the study. In addition, one patient was implanted with a Heartware® outside the study period. 
Size of pump 10 mL, n (%) 
Survival, etiology and heart disease
A 75% survival to discharge after transplant was observed for our VAD patients (BiVAD: 21/27, 77.8% and single VAD: 6/9, 66.6%) ( Table 2 and Fig. 1 ). There were no deaths after transplant prior to discharge. The median duration of VAD support among the non-survivors was 14 vs. 63 days in the survivors (p = 0.03). Patient diagnosis included dilated cardiomyopathy (n = 19, 53%), congenital heart disease (CHD) (n = 12, 33%) chemotherapy induced cardiomyopathy (n = 2, 5.5%) and other (n = 3, 8.5%) ( Table 1) . CHD anatomies included Shone's complex, truncus arteriosus, myocardial bridges with poor ventricular function, anomalous left coronary artery from the pulmonary artery, transposition of great arteries with a VSD s/p neonatal repair and Ebstein's anomaly. Five patients (14%) had single ventricle physiology with 4 having hypoplastic left heart syndrome (HLHS). The survival to discharge among patients with dilated cardiomyopathy was 100%. Five (41.7%) of the 12 patients with CHD survived to discharge. Of the 7 CHD deaths, 3 patients had single ventricle physiology.
Mechanical ventilation and VAD support
The median duration of mechanical ventilation pre-and post-implant was 7.5 [1.8,19 ] and 6 [3, 11] days in the whole cohort, respectively (Tables 3 and 4) . Pre-implant, the duration of mechanical ventilation did not differ between survivors and non-survivors (6 (1.5,18.5) days vs. 10 (5,29) days, respectively, p = 0.44). Post-implant, the duration of mechanical ventilation was trended higher in non-survivors [10 (4,14) days in non-survivors vs. 6 (2,8) days in survivors, p = 0.08]. The number of patients in respiratory failure (Intermacs criteria) was significantly higher in non-survivors (100% of non-survivors vs 52% of survivors, p = 0.014) There were two instances of the use of high frequency oscillator for respiratory support, both non-survivors.
Acute kidney injury and VAD support
Twenty-nine patients (81%) in the whole group had some degree of acute kidney injury (AKI) at implantation with 11 patients in failure (F) and 2 in loss of function (L) category. At 14 days post-implantation, 13% (3 patients) among the survivors were either in loss of function or failure group, as compared to 50% (3 patients) among the non-survivors (p = 0.19) ( Table 4) . When comparing RIFLE score at time of transplant or death, the number of survivors in the normal or risk categories was trended higher as compared to non-survivors (74% vs. 22%, p = 0.06).
Five of the non-survivors needed renal replacement therapy (RRT) pre-VAD placement, which increased to 7 after VAD implant; none of them were able to wean off renal support. The longest need for RRT in a survivor was 22 days post-VAD placement.
Hepatic injury and VAD support
Pre-implant increase in liver enzymes was similar for survivors and non-survivors (7 (25%) vs. 2 (22%), respectively, p = 1). Median peak bilirubin levels pre-implant were also similar between survivors and non survivors (2.3 (1.5,3.3) vs 2.8 (1.3, 4.5), respectively (p = 0.94)). Similarly, the number of patients with post-implant elevation of AST and ALT did not differ between survivors and non-survivors (3 (12.5%) vs. 2 (22%), respectively, p = 0.58). Importantly, peak bilirubin levels in the first week post-implant trended lower in survivors vs non-survivors (2.3 (1.8,3.2) vs 6.1 (2.7, 8.3), respectively (p = 0.06)) ( Table 4) . Hepatic imaging pre-and post-implant by ultrasound was used in a few patients with all of them being negative for any pathology isolated to the liver.
Bleeding and infectious complications
Complications observed during VAD support were major bleeding (11/36; 31%) and infections (19/36; 52%) ( Table 5 ). Of the 19 culture-proven infection, 5 patients had clinical septicemia and 9 patients had positive endotracheal cultures. There was one localized non-device infection, 3 percutaneous site infections and no internal pump infection. The most common blood borne pathogen was Enterobacteriaceae including Enterobacter, Proteus and Serratia. There were 2 instances of fungal sepsis caused by Candida albicans. The common pathogen responsible for percutaneous site infection and respiratory infection was Staphylococcus aureus.
Neurological complications and follow up POPC score
Neurologic complications were observed in 11 patients (33%) ( Table  5 ). Strokes comprised 72% (8 of 11 patients) of the neurological events with one stroke becoming hemorrhagic (Table 5 ). Among the patients with a stroke, three presented with new focal deficits, three with new onset seizures, one with isolated encephalopathy and one detected during surveillance. Two of the patients with a hemorrhagic event presented with new focal deficits and one with severe headache. One of the three patients with a hemorrhagic event did not survive to transplant. One patient had a relatively small bleed and has a normal neurological follow up. The other survivor recovered after an initial severe insult and had a POPC of 3 at follow up. Seventeen (63%) of the survivors had a POPC score of 1, 5 (18.5%) showed a POPC of 2 and 5 (18.5%) showed a POPC of 3. The median duration of follow up for neurological follow was 2.2 years (0.25, 5.25). Of the five patients with a POPC score of 3, three had strokes post-VAD placement, one had a hemorrhagic event and one patient with unclear insult.
Prognostic features
Multivariate analysis was not possible given our small sample size. Univariate analysis showed pre-implantation diagnosis of CHD, open chest post-implant, respiratory failure post-implant (INTERMACS criteria) and prior cardiac surgery as risk factors for mortality. CPR pre-implantation was associated with mortality in our population.
Factors showing a trend to clinical significance included diagnosis of SV, smaller BSA, post-implant higher peak total bilirubin, and (RIFLE R) or normal renal function at the time of transplant or death. Table 6 includes the list of all non-survivors. *One patient had a stroke which converted to hemorrhage. Most complications were numerically greater among non-survivors, although statistical significance was not achieved. 
Discussion
Similar to other centers, patients with dilated cardiomyopathy were our single largest subset and exhibited the best survival rate [13, 14] . The next largest cohort included patients with congenital heart disease and exhibited a 43% and 40% survival in biventricular and single ventricular physiology, respectively, which is comparable to Almond et al. [15, 16] . Our cohort, like other intuitional experiences, demonstrated that CHD as an etiology for needing VAD support is a predictor of poor prognosis. Other significant factors like smaller BSA, previous cardiac surgery and diagnosis of single ventricle are likely related to the diagnosis of CHD.
Non-survivors had a longer median duration of intubation both preand post-VAD placement, although clinical significance was noted only in the duration post-VAD placement. Prodhan et al. noted that patients with a need for ECMO prior to VAD implantation needed prolonged mechanical ventilation post-VAD [17] . A similar pattern was noted in our patients with 8 of 12 patients supported on ECMO pre-VAD needing mechanical ventilation beyond 7 days. We propose that the increased duration of postoperative respiratory support in non-survivors likely indicates the severity of multi-organ dysfunction sustained perioperatively during implant.
AKI pre-VAD implant was comparable in both groups, but normal/at risk renal function as defined by the pRIFLE score at time of primary end-point was trended higher for survivors. Adult literature describes AKI at day 7 post-VAD placement as an independent predictor of 30 day mortality [18] . Based on our current study, we propose that persistent renal failure post-implant can indicate poor outcome. Although the 2-week time-point was not significant in our data set for AKI, we expect this to be a reasonable timeframe for renal recovery considering the median period of non-survivors on VAD support was 14 days. In addition, 3 of our non-survivors had already expired by 14 days, with all three of them in pRIFLE category F. Importantly, 6 of 7 survivors needing RRT at implant came off dialysis within 14 days post-implantation as opposed to none of the five among the non-survivors.
Peak bilirubin in the perioperative phase following VAD placement also trended higher in non-survivors, indicating ongoing congestive hepatopathy despite support. Hepatic dysfunction prior to VAD support has been shown to be a key determinant in outcomes [19] . Using the Model of End-stage Liver Disease excluding INR (MELD-XI) score, Yang et al. has demonstrated that persistent liver dysfunction post-VAD indicates a poor candidate for transplant [20] . Conway et al. noted pre-implant increase in bilirubin as an independent factor of mortality in children b10 kg receiving a Berlin Excor VAD [21] . Bilirubin levels post-implant reflects unloading of the right sided circulation, which may be incomplete in a restrictive physiology from a thick ventricle or congenitally malformed heart.
The rates of infection and bleeding complications were comparable across both survivors and non-survivors. Overall, we noted a higher incidence of infections as compared to Zafar et al. in their description of the use of biventricular ventricular therapy which is similar to our cohort [22] . This could likely be due to our practice to keep indwelling PICC lines in children with VADs, which is a system process now in transition. Neurological complications were also similar in both groups and showed no association with mortality.
Multi-institutional and multicenter data have provided insight into the prognostic features of survival post-implant. Stein et al. noted that higher incidence of complications 30 days after implant was associated with poor outcome [23] . Our data for complications was analyzed for total number of complications rather than complications during a particular timeframe. Fan et al. noted that increased central venous pressures (CVP) pre-implant was associated with increased mortality likely due to increased filling pressures affecting function of the liver, kidney and liver [24] . Our data showed CPR pre-VAD as the only preimplantation factor associated with mortality.
The retrospective nature, lack of non-pulsatile devices and the small sample size of our group are some of its many limitations. In addition, there is a large variation in BSA and age in our cohort with the diagnosis of CHD limited to the smaller ages. Midway through our study period, there was a change in the device used for supportive care, which could alter the post-VAD clinical recovery and outcome. Patients supported with the Thoratec VAD system were bigger adolescents with myocardial dysfunction in structurally normal heart.
Conclusion
Our experience contributes to the ever-growing body of evidence that VADs are an efficient and safe bridge to pediatric heart transplantation in dilated cardiomyopathy. End-organ dysfunction in the first two weeks post-VAD placement can be useful in prognosticating survival to cardiac transplant. Renal recovery within the first two weeks, peak total bilirubin in the first week post-VAD placement and persistent respiratory failure after the first 7 days can be useful markers of prognosis. This, in the context of median duration of VAD support among nonsurvivors being 14 days, guides our recommendation that the twoweek period can be a benchmark to patient prognosis. Ongoing analysis of multicenter databases will likely indicate a clearer trend.
